Indian anticoagulants market is estimated to grow at a CAGR of 8.8% during the forecast period. A significant rise in the demand for novel oral anticoagulants has been witnessed owing to its demonstrated safety and efficacy in trials and Indian government initiatives to reduce the prices of NOSCs. NOACs may be safer for patients as there is a low risk of bleeding, and these anticoagulants may also be highly effective for the prevention of blood clots compared to warfarin. NOACs are the ideal suggested drug class compared to warfarin, except for patients suffering from moderate to severe mitral stenosis or an artificial heart valve.
A full report of Indian Anticoagulants Market is available at: https://www.omrglobal.com/industry-reports/indian-anticoagulants-market
NOACs comprises edoxaban, dabigatran, apixaban, and rivaroxaban. In July 2018, the Indian government has decreased the cost of one of the three drugs that are being prescribed in India by one-third. The Indian government has decreased the Dabigatran cost from nearly $1 per tablet to nearly $0.3. Over the 10 years, some evidence has suggested that NOACs could reduce the risk of stroke. Therefore, in 2018, the government has lowered the price of NOSCs in India, which is supporting to drive market growth.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/indian-anticoagulants-market
Scope of the Indian Anticoagulants Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Competitive Landscape- Cipla Ltd., Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH
Recent Strategic Initiatives in the Indian Anticoagulants Market
- In June 2020, Gland Pharma Ltd. along with its partners Athenex Pharmaceutical Division and MAIA Pharmaceuticals Inc declared the introduction of a ready-to-use Bivalirudin injection in the US. This injection is intended for use as an anticoagulant among patients who are experiencing percutaneous coronary intervention (PCI), which includes patients suffering from heparin-induced thrombocytopenia and thrombosis syndrome, and heparin-induced thrombocytopenia.
- In October 2019, Morepen Labs has added three new drugs, including UDCA (for liver ailments), Rivaroxaban (cardiac segment), and Vildagliptin (diabetes segment) to its active pharmaceutical ingredients (API) portfolio. Rivaroxaban is an anticoagulant which is a blood thinner.
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Indian Anticoagulants Market-Segmentation
By Type
- Novel Oral Anticoagulants (NOACs)
- Vitamin K Antagonist
- Heparin and Low Molecular Weight Heparin (LMWH)
By Application
- Pulmonary Embolism
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
